science wire

With the help of sponges inserted in the bloodstream to absorb excess drugs, doctors are hoping to prevent the dangerous side effects of toxic chemotherapy agents or even deliver higher doses to knock back tumors, like liver cancer, that don't respond to more benign treatments. The "drug sponge" is an absorbent polymer coating a cylinder that is 3D printed to fit precisely in a vein that carries the blood flowing out of the target organ - the liver in liver cancer, for example.

Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease   Sickle cell VOCs, which are triggered

ReSET-O(TM)* is the first US FDA-cleared prescription digital therapeutic for patients with Opioid Use Disorder Cleared by the FDA in December, reSET-O is available immediately As part of a broader f

Basel, December 21, 2018 - Novartis today announced that the European Commission (EC) approved an expanded indication for Kisqali  (ribociclib), the CDK4/6 inhibitor with the largest body of first-li

Proposed acquisition builds on existing agreement with CellforCure for contract manufacturing of Novartis leading CAR-T cell therapy Kymriah (tisagenlecleucel) and recent successful completion of tec

Doctors may be able to assess the survival rates of melanoma patients following the discovery of a molecule that allows the cancer to spread from the skin to other parts of the body.

A new Canadian study, led by a team at the Research Institute of the McGill University Health Centre (RI-MUHC), is shedding light on anaphylaxis due to an unknown trigger (AUT)-an unpredictable and potentially fatal allergic reaction, about which surprisingly little is known.

PRIME designation granted by European Medicines Agency for Roche's risdiplam for treatment of spinal muscular atrophy (SMA) Risdiplam has the potential to be the first oral medicine for the treatment

Adaptive Phage Therapeutics Enters into Collaboration Agreement with Researchers at Yale University to Manufacture and Supply Therapeutic Bacteriophage View this release on BusinessWire   Gaithersbur

The EC approval underscores the long-term safety and efficacy of Xolair demonstrated in clinical studies and by 13 years of real-world use in Europe   Xolair (omalizumab) prefilled syringe (PFS) is t

If someone told you there was a vaccine that could prevent most cases of cervical cancer-and a growing number of head and neck cancers-would you get it?

Dangerous antibiotic-resistant bacteria could soon be targeted with a drug initially developed to treat Alzheimer's disease.

ReSET-O TM is the first FDA-cleared Prescription Digital Therapeutic (PDT) for patients with Opioid Use Disorder Pear Therapeutics is leading the development of a new therapeutic class with two FDA-a

University News Rev. James Lawson Jr., civil rights icon, champion of nonviolence, receives UCLA Medal Arts + Culture Historian helps create archive at UCLA of South African propaganda comics from th

  Subgroup analyses of three pivotal Phase III MONALEESA trials showed Kisqali plus endocrine therapy extended PFS in all patients with and without visceral involvement compared to endocrine therapy

Research done by Prof. Dirk Prüfer and his team makes transfer possible / "Taraxagum project is an outstanding example of the way that Münster University stands for top-level research" Years ago, the idea sounded anything from weird to audacious: manufacturing car tyres from dandelions.

Approval based on survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (NSCLC) with n

The first Generet Award, which was launched this year, has gone to Professor Miikka Vikkula (de Duve Institute - UCLouvain) for his research seeking a genetic explanation for vascular anomalies.

UK-led research is taking place on the International Space Station (ISS) for the first time, following a successful launch from Kennedy Space Centre at Cape Canaveral in the US. An experiment using microscopic nematode worms involving teams of scientists from the Universities of Nottingham, Exeter and Lancaster was among a shipment of cargo and scientific investigations to be delivered to the ISS by the SpaceX Dragon spacecraft following the launch by the SpaceX Falcon 9 rocket at 6.16 pm (UK time) on Wednesday 5 December.

At three years, 88.3% of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0% treated with Her

Internationally renowned researcher Anne Skaja Robinson has joined Carnegie Mellon University as head of its Department of Chemical Engineering.

Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizum

PEARL 1 and PEARL 2, the largest pivotal trials to date in chronic spontaneous urticaria (CSU), will enroll more than 2,000 CSU patients ,   Ligelizumab (QGE031), a monoclonal antibody, is being deve

New analyses from the phase III MURANO study in previously treated chronic lymphocytic leukaemia show continued benefit from fixed-duration regimen after a median follow-up of three years Updated res

Nearly 77% of children receiving Hemlibra once weekly experienced zero treated bleeds Hemlibra once weekly reduced treated bleeds by 99% compared to prior bypassing agents in a prospective intra-pati

Polatuzumab vedotin in combination with MabThera/Rituxan (rituximab) plus bendamustine more than doubled overall survival, compared to MabThera/Rituxan plus bendamustine alone in the phase Ib/II GO29365 study Polatuzumab vedotin has the potential to provide a promising new treatment option at first relapse Results from the GO29365 study, the first and only randomised study to suggest a survival benefit for patients not eligible for a haematopoie

The AVXS-101, now known as ZOLGENSMA (onasemnogene abeparvovec-xxxx) , filing is supported by data from the START trial which demonstrated a dramatic increase in survival and transformative improvement in achievement of developmental milestones compared to the natural history of SMA Type 1   SMA Type 1 is a progressive neuromuscular disease and the leading cause of genetic mortality in infants globally   ZOLGENSMA represents the first in a propr

Revolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs.

In the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r ALL; relapse-free survival was 62% at 24 months, with median duration of

New post-hoc analysis of SUSTAIN study, presented at ASH 2018, highlights results among patients who were treated per protocol compared with all randomized patients Crizanlizumab, a monthly infusion

Here's a batch of fresh news and announcements from across Imperial. From a geological Brexit study captured in clay, to student solutions to global humanitarian aid challenges, here is some quick-read news from across the College.

Mirati Therapeutics, Inc. has been announced as the latest partner of Cancer Research UK's Stratified Medicine Programme which is being carried out in collaboration with the University of Birmingham Cancer Research Clinical Trials Unit.

Students Aim To Create Preemptive Tool To ID High-risk Users Carnegie Mellon University students have created a new tool to help clinicians identify individuals with high-risk patterns of opioid use before it's too late.

Approval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-f

Luxturna* (voretigene neparvovec) is the first gene therapy to treat an inherited retinal disease, indicated for children and adults with vision loss caused by mutations in both copies of the RPE65 g

University of Queensland researchers are conducting the Queensland trial of a new treatment for Obsessive-Compulsive Disorder (OCD) using an amino acid supplement.

Humpback whales sing increasingly complex songs, but University of Queensland researchers have discovered they may suddenly switch to something simpler, in a 'cultural revolution'.

Approval based on two studies that showed durable remissions in people with newly-diagnosed acute myeloid leukaemia, who are age 75 years or older, or for those ineligible for intensive induction che

When Shakespeare and science collide - that's the essence of a new opera coming to Nottingham Lakeside Arts' Djanogly Theatre on University Park on Tuesday 27 November 2018.

A world-first clinical trial of a new cellular immunotherapy for multiple sclerosis (MS) has improved symptoms and quality of life for the majority of patients. The treatment targets the Epstein-Barr virus (EBV), and is based on a theory formulated by University of Queensland and Royal Brisbane and Women's Hospital (RBWH) researcher Professor Michael Pender.

ReSET is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD) Adding reSET to outpatient therapy significantly improved abstinence in substances of abus